Osimertinib is suggested as a first-line therapy for advanced EGFR-mutated NSCLC patients because a pivotal clinical trial (FLAURA) showed that osimertinib had a median PFS of 18.9 months and OS of 38.6 months, which were significantly longer than those of comparator therapies (10.2 months of median PFS and 31.8 months of median OS) (33). Here, EGFR is linked to non-small cell lung carcinoma.